Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study
Authors:
Open Access
- 19 March 2022
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 61, 103755
Abstract
No abstract availableKeywords
Funding Information
- Suomen Kulttuurirahasto
- Merck
- Merck KGaA
This publication has 16 references indexed in Scilit:
- Fingolimod Rebound: A Review of the Clinical Experience and Management ConsiderationsNeurology and Therapy, 2019
- Multiple sclerosis in Finland 2018—Data from the national registerActa Neurologica Scandinavica, 2019
- Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosisMultiple Sclerosis and Related Disorders, 2019
- Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysisMultiple Sclerosis and Related Disorders, 2019
- Cladribine tablets added to IFN-β in active relapsing MSNeurology Neuroimmunology & Neuroinflammation, 2018
- Cladribine treatment of multiple sclerosis is associated with depletion of memory B cellsJournal of Neurology, 2018
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyMultiple Sclerosis Journal, 2017
- Both cladribine and alemtuzumab may effect MS via B-cell depletionNeurology Neuroimmunology & Neuroinflammation, 2017
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsAnnals of Neurology, 2016
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010